Charles River Laboratories has partnered with digital pathology company Deciphex to introduce Patholytix Foresight, a non-clinical AI decision support tool designed to enhance toxicologic pathology assessments. 

This tool is intended to help accelerate primary evaluation and peer review processes, thereby facilitating faster decision-making in drug discovery and safety assessment. 

Patholytix Foresight provides toxicologic pathologists with advanced visual tools that promote efficiency, consistency, and accuracy in their assessments. 

Charles River chief scientific officer and corporate senior vice-president Julie Frearson said: “AI-powered solutions are accelerating the pace and efficiency of drug development, and the launch of Patholytix Foresight marks a significant milestone in our collaborative efforts to enhance the digital transformation of toxicological pathology.” 

The tool leverages an extensive data warehouse to incorporate organ-based lesion classifiers. It is built on Deciphex's non-clinical workflow platform, Patholytix 4.0.  

Patholytix Foresight also integrates AI classifiers with Whole Slide Images (WSI) to streamline workflows and assist pathologists in identifying critical features in tissue samples. 

Deciphex chief scientific officer Pierre Moulin said: “In collaboration with Charles River Laboratories, we look forward to bringing Patholytix Foresight to the forefront of digital pathology, empowering pathologists worldwide with cutting-edge AI technology for more efficient and accurate toxicological assessments.  

“This advance is part of our collective vision to enable AI-empowered and regulated digital primary review of safety studies.” 

In February 2024, Diagnexia signed a collaborative agreement with Kenya's Aga Khan University Hospital to enhance pathology services and spearhead advancements in AI-driven diagnostics.